Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

ONCONEPHROLOGY

Immune-based combination therapy for metastatic kidney cancer

Nature Reviews Nephrology volume 15, pages 324–325 (2019)Cite this article

Subjects

New data from the JAVELIN Renal 101 and KEYNOTE-426 trials provide evidence that immune-based combination therapy has superior efficacy to sunitinib monotherapy in patients with advanced renal cell carcinoma. The new findings raise important questions regarding the optimum choice of combination therapy for these patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Mechanisms of action of agents used in combination therapies for metastatic RCC.

References

  1. Motzer, R. J. et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1103–1115 (2019).

    Article  CAS  Google Scholar 

  2. Rini, B. I. et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med. 380, 1116–1127 (2019).

    Article  CAS  Google Scholar 

  3. Motzer, R. J. et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N. Engl. J. Med. 378, 1277–1290 (2019).

    Article  Google Scholar 

  4. Tannir, N. M. et al. Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab+ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC) [abstract]. J. Clin. Oncol. 37 (Suppl. 7), 547 (2019).

    Article  Google Scholar 

  5. Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).

    Article  Google Scholar 

  6. Das, R. et al. Combination therapy with anti-CTLA4 and anti-PD1 leads to distinct immunologic changes in-vivo. J. Immunol. 194, 950–959 (2015).

    Article  CAS  Google Scholar 

  7. de Coaña, Y. P. et al. Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma. Oncotarget 8, 21539–21553 (2017).

    Article  Google Scholar 

  8. Fisher, R. I., Rosenberg, S. A. & Fyfe, G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J. Sci. Am. 6 (Suppl. 1), 55–57 (2000).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy

    Camillo Porta

  2. Division of Translational Oncology, IRCCS Istituti Clinici Scientifici Maugeri, Pavia, Italy

    Camillo Porta & Mimma Rizzo

Authors
  1. Camillo Porta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mimma Rizzo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Camillo Porta.

Ethics declarations

Competing interests

C.P. has acted as a consultant and/or speaker for Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, Ipsen, Eisai, Novartis, EUSA, Janssen, and GE. M.R. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Porta, C., Rizzo, M. Immune-based combination therapy for metastatic kidney cancer. Nat Rev Nephrol 15, 324–325 (2019). https://doi.org/10.1038/s41581-019-0149-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41581-019-0149-0

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing